Phase I Clinical Trial Assessing the Safety and Feasibility of Intramuscular pNGVL4aCRTE6E7L2 and TA-CIN Administration for the Treatment of Patients With Persistent HPV16+ ASC-US or LSIL
Latest Information Update: 01 Jul 2025
At a glance
- Drugs Human papillomavirus vaccine (Primary) ; PVX 6 (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Acronyms PVX-6
- Sponsors PAPIVAX
Most Recent Events
- 26 Jun 2025 Planned End Date changed from 1 Sep 2025 to 1 Sep 2027.
- 26 Jun 2025 Planned primary completion date changed from 1 May 2025 to 1 May 2027.
- 30 Jan 2025 Planned End Date changed from 28 Feb 2025 to 1 Sep 2025.